 |
 |
   |
About MacuSight
|
MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. At the same time, MacuSight focuses on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates. MacuSight's lead development program is focused on advancing sirolimus (rapamycin) as a potential next-generation therapeutic for the treatment and prevention of wet age-related macular degeneration (wet AMD) and the treatment of diabetic macular edema (DME), a manifestation of diabetic retinopathy. MacuSight has completed two Phase 1 clinical trials of its sirolimus product candidate in patients with wet AMD and DME. Findings from both studies demonstrated the product to be safe and well-tolerated in all doses tested with two different routes of administration (subconjunctival injection and intravitreal injection). In addition, investigators from both studies noted improvements in visual acuity consistent with anatomical retinal and foveal changes following a single administration of sirolimus. Importantly, these findings were similar for patients receiving sirolimus via either intravitreal injections or less-invasive, more convenient subconjunctival injections. These positive results for sirolimus delivered with subconjunctival injection provide the first evidence for the potential of treating retinal disease without direct injection into the back of the eye. Based on the positive results from its Phase 1 trials, MacuSight is initiating Phase 2 studies in DME and wet AMD, as well as additional ocular diseases and conditions. |
   "MacuSight is a pharmaceutical company focused on the development of innovative therapeutic products for the treatment of severe ocular diseases and conditions." |